Carotid versus femoral access for transcatheter aortic valve replacement: comparable results in the current era. (16th March 2021)

• Record Type: Journal Article
• Authors: Marie, Basile; David, Charles Henri; Guimbretière, Guillaume; Foucher, Yohann; Buschiazzo, Antoine; Letocart, Vincent; Manigold, Thibaut; Plessis, Julien; Jaafar, Philippe; Morin, Hélène; Rozec, Bertrand; Roussel, Jean Christian; Sénage, Thomas
• Is Part Of: European journal of cardio-thoracic surgery. Volume 60:Number 4(2021)
• Page Start: 874
• Page End: 879
• Publication Date: 2021-03-16
• Subjects: Transcatheter aortic valve implantation -- Transcatheter aortic valve replacement -- Trans-carotid -- Transfemoral -- Vascular complications -- 30 days outcomes; Heart -- Surgery -- Periodicals; Chest -- Surgery -- Periodicals; 617.54
• DOI: 10.1093/ejcts/ezab109
• Languages: English
• ISSNs: 1010-7940

Abstract

Abstract: : OBJECTIVES: The carotid approach for transcatheter aortic valve replacement (TAVR) has been shown to be feasible and safe. The goal of this study was to compare the 30-day outcomes of trans-carotid (TC) and transfemoral (TF) TAVR. METHODS: This retrospective study enrolled 500 consecutive patients treated by TC-TAVR ( n = 100) or TF-TAVR ( n = 400) with percutaneous closure between January 2018 and January 2020 at the Nantes University Hospital. The primary end-point was the occurrence of cardiovascular death and cerebrovascular events at 30 days. RESULTS: The mean age was 79.9 ± 8.1 in the TC group and 81.3 ± 6.9 ( P = 0.069) in the TF group. The TC group had more men (69% vs 50.5%; P = 0.001) and more patients with peripheral vascular disease (86% vs 14.8%; P < 0.0001). Cardiac characteristics were similar between the groups, and the EuroSCORE II was 3.8 ± 2.6% vs 4.6 ± 6.0%, respectively ( P = 0.443). The 30-day mortality was 2% in the TC group versus 1% in the TF group ( P = 0.345). TC-TAVR was not associated with an increased risk of stroke (2% vs 2.5%; P = 0.999) or major vascular complications (2% vs 4%; P = 0.548). More permanent pacemakers were implanted in the TF group (14.9% vs 5.6%; P = 0.015), and no moderate or severe aortic regurgitation was observed in the TC group (0 vs 3.3%; P = 0.08). TC-TAVR was not associated with an increased risk of mortality or stroke at 30 days (odds ratio 1.32; 95% confidence interval 0.42–4.21; P = 0.63) in the multivariable analysis. CONCLUSIONS: No statistically significant differences between TC-TAVR and TF-TAVR were observed; therefore, TC-TAVR should be the first alternative in patients with anatomical contraindications to the femoral route.